Mari Manuia

Genomics Institute of the Novartis Research Foundation — United States

Medicine · Health Sciences

8h-index1.5kcitations24works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(15), Cancer therapeutics and mechanisms(6), Click Chemistry and Applications(5), Monoclonal and Polyclonal Antibodies Research(4), Lung Cancer Research Studies(4)

Publications24 total

High-throughput assay for measuring target occupancy of covalent compounds: a case study with MK2
RSC Chemical Biology·2026Open Access
Data from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Table 1 from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Data from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Figure Legends from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Figures 1 through 5 from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Table 1 from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Material and Methods from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Material and Methods from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Figures 1 through 5 from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Figure Legends from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Structure-Based Design of Selective LONP1 Inhibitors for Probing <i>In Vitro</i> Biology
Journal of Medicinal Chemistry·2021· 17 citedOpen Access
Discovery of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
Journal of Medicinal Chemistry·2016· 94 citedOpen Access
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Nature·2016· 851 citedOpen Access
EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
Cancer Research·2016· 120 citedOpen Access
EGF816, an irreversible mutant-selective EGFR inhibitor, is effective in NSCLC with both primary activating and T790M-mediated resistant EGFR mutations
2016
HTRF Kinase Assay Development and Methods in Inhibitor Characterization
Methods in molecular biology·2015· 12 cited
Abstract 1734: <i>In vitro</i> characterization of EGF816, a third-generation mutant-selective EGFR inhibitor
Cancer Research·2014· 4 cited
Superoxide dismutase 1 (SOD1) is essential for H <sub>2</sub> O <sub>2</sub> -mediated oxidation and inactivation of phosphatases in growth factor signaling
Proceedings of the National Academy of Sciences·2008· 255 citedOpen Access
Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth
Clinical Cancer Research·2008· 91 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

G. Lelais(16), Matthew McNeill(16), Michael DiDonato(15), Badry Bursulaya(15), Pierre‐Yves Michellys(15), Robert Epple(15), Thomas H. Marsilje(15), Shailaja Kasibhatla(14), Debbie Liao(13), Nazima Pathan(13), Matthew J. Niederst(12), Celin Tompkins(12), Noelito Timple(12), Mei-Ting Vaillancourt(12), AnneMarie Culazzo Pferdekamper(12), Elizabeth L. Lockerman(12), Chun Li(12), Carlotta Costa(12), Jordi Barretina(12), Jeffrey A. Engelman(12)